Milacemide

• CAT Number: I032279
• CAS Number: 76990-56-2
• Molecular Formula: C7H16N2O
• Molecular Weight: 144.22
• Purity: 98%
• Synonyms: Milacemide; CP1552 S; CP-1552 S; CP 1552 S
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 2-(pentylamino)acetamide
• InChI: InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10)
• InChIKey: GJNNXIYZWIZFRH-UHFFFAOYSA-N
• SMILES: CCCCCNCC(=O)N

Milacemide（Cat No.:I032279）is a synthetic compound and a prodrug of the neuroactive amino acid glycine. It acts as a glycine transporter inhibitor and is primarily studied for its potential to enhance cognitive function and treat neurodegenerative conditions. Milacemide is thought to work by increasing glycine levels in the brain, which can modulate N-methyl-D-aspartate (NMDA) receptor activity, a pathway involved in learning, memory, and neuronal survival. It has been investigated in clinical trials for conditions like Alzheimer’s disease and cognitive impairment, although its therapeutic use and long-term safety are still under evaluation.

Reference

1.Milacemide, a glycine pro-drug, inhibits strychnine-allodynia without affecting normal nociception in the rat.
Khandwala H, Loomis CW.
Pain. 1998 Jul;77(1):87-95. doi: 10.1016/S0304-3959(98)00086-4.
PMID: 9755023
2.Milacemide enhances memory storage and alleviates spontaneous forgetting in mice.
Quartermain D, Nuygen T, Sheu J, Herting RL.
Pharmacol Biochem Behav. 1991 May;39(1):31-5. doi: 10.1016/0091-3057(91)90393-g.
PMID: 1833781
3.Microionophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells.
Godfraind JM.
Br J Pharmacol. 1990 May;100(1):119-25. doi: 10.1111/j.1476-5381.1990.tb12062.x.
PMID: 2196964 Free PMC article.
4.Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.
Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, Skare S, Fakouhi JD, Herting RL.
J Am Geriatr Soc. 1992 May;40(5):503-6. doi: 10.1111/j.1532-5415.1992.tb02019.x.
PMID: 1634705 Clinical Trial.
5.Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia.
Herting RL.
Ann N Y Acad Sci. 1991;640:237-40. doi: 10.1111/j.1749-6632.1991.tb00225.x.
PMID: 1837978 Clinical Trial.
6.The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B.
Janssens de Varebeke P, Pauwels G, Buyse C, David-Remacle M, De Mey J, Roba J, Youdim MB.
J Neurochem. 1989 Oct;53(4):1109-16. doi: 10.1111/j.1471-4159.1989.tb07403.x.
PMID: 2769256
7.Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B.
Janssens de Varebeke P, Cavalier R, David-Remacle M, Youdim MB.
J Neurochem. 1988 Apr;50(4):1011-6. doi: 10.1111/j.1471-4159.1988.tb10566.x.
PMID: 3346666
8.Cognitive effects of milacemide and methylphenidate in healthy young adults.
Camp-Bruno JA, Herting RL.
Psychopharmacology (Berl). 1994 Jun;115(1-2):46-52. doi: 10.1007/BF02244750.
PMID: 7862911 Clinical Trial.
9.Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?
O’Brien EM, Tipton KF, Strolin Benedetti M, Bonsignori A, Marrari P, Dostert P.
Biochem Pharmacol. 1991 Jun 1;41(11):1731-7. doi: 10.1016/0006-2952(91)90177-7.
PMID: 2043162
10.Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B.
O’Brien EM, Dostert P, Tipton KF.
Biochem Pharmacol. 1995 Jul 31;50(3):317-24. doi: 10.1016/0006-2952(95)00145-p.
PMID: 7646533